The essence of ICI is a branch of mAbs, specifically promoting anti-tumor T-cell responses and response factors by targeting negative regulatory proteins (ICP: CTLA-4, PD-1/PD-L1) [230]. The gene discussed is CD274; the disease is neoplasm.